ArticleDigestive diseases and sciences2019
CircScd1 Promotes Fatty Liver Disease via the Janus Kinase 2/Signal Transducer and Activator of Transcription 5 Pathway.
Article in Digestive diseases and sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 54 citations in OpenAlex.
- Role of Circular RNAs in Liver Diseases.International journal of medical sciences · 2026Review
- Advances in the Regulation of Lipid Metabolism by Non-Coding RNAs.Animals : an open access journal from MDPI · 2025Review
- Expression profile and N6-methyadenosine modification of circular RNA analysis in MAFLD.BMC gastroenterology · 2025Article
- Unraveling Metabolic Dysfunction-Associated Steatotic Liver Disease Through the Use of Omics Technologies.International journal of molecular sciences · 2025Review
- Inhibition of mmu_circ_0009303 improves metabolic dysfunction-associated steatotic liver disease by regulating lipid metabolism and oxidative stress.Endocrine journal · 2025Article
- Circular RNAs in Liver Diseases.Advances in experimental medicine and biology · 2025Review
- Review
- Circular RNAs in human diseases.MedComm · 2024Review
- Circular RNAs in non-alcoholic fatty liver disease: Functions and clinical significance.RNA biology · 2024Review
- Interference of a mammalian circRNA regulates lipid metabolism reprogramming by targeting miR-24-3p/Igf2/PI3K-AKT-mTOR and Igf2bp2/Ucp1 axis.Cellular and molecular life sciences : CMLS · 2023Article
- Circular RNA as a Novel Regulator and Promising Biomarker in Polycystic Ovary Syndrome.Biomolecules · 2023Review
- CircRNA-PI4KB Induces Hepatic Lipid Deposition in Non-Alcoholic Fatty Liver Disease by Transporting miRNA-122 to Extra-Hepatocytes.International journal of molecular sciences · 2023Article
- Advances in the regulation of adipogenesis and lipid metabolism by exosomal ncRNAs and their role in related metabolic diseases.Frontiers in cell and developmental biology · 2023Review
- Comprehensive Analysis of circRNA Expression Profiles in Human Brown Adipose Tissue.Diabetes, metabolic syndrome and obesity : targets and therapy · 2023Article
- Circular RNAs in hepatocellular carcinoma: biogenesis, function, and pathology.Frontiers in genetics · 2023Review
- [Regulatory mechanism and potential value of circular RNA in nonalcoholic fatty liver disease progression].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2022Review
- Chi-Circ_0006511 Positively Regulates the Differentiation of Goat Intramuscular Adipocytes via Novel-miR-87/CD36 Axis.International journal of molecular sciences · 2022Article
- Noncoding RNAs as additional mediators of epigenetic regulation in nonalcoholic fatty liver disease.World journal of gastroenterology · 2022Review
- Emerging functions of circular RNA in the regulation of adipocyte metabolism and obesity.Cell death discovery · 2022Review
- Emergent Roles of Circular RNAs in Metabolism and Metabolic Disorders.International journal of molecular sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNonalcoholic fatty liver disease (NAFLD) is one of the most common liver diseases in affluent countries. Recent studies have reported that circular RNAs (circRNAs) are important regulators of hepatic steatosis. However, the role and mechanism of circRNA in NAFLD are poorly understood.
aimsThis study is to reveal the role and mechanism of circRNA in NAFLD.
methodsThrough NAFLD-related circRNA microarrays, we used real-time quantitative reverse transcription-polymerase chain reaction to screen circScd1 levels in control and test groups of mice fed a high-fat diet. RNA interference and over-expression plasmid vectors were used to manipulate the expression of circScd1, and the biological effects were evaluated by oil red staining, triglyceride detection, and western blot analysis.
resultsCircScd1 expression was significantly lower in NAFLD tissues than in control tissues. Moreover, over-expression of circScd1 significantly inhibited the formation of lipid droplets. Western blot analyses showed that the protein levels of Janus kinase 2 (JAK2) and signal transducer and activator of transcription 5 (STAT5) were significantly increased. However, knockdown of circScd1 significantly promoted the degree of hepatocellular lipidosis and reduced the expression levels of JAK2 and STAT5.
conclusionsAberrant expression of circScd1 affects the extent of hepatocellular lipidosis in NAFLD and promotes fatty liver disease via the JAK2/STAT5 pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.